Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06410924 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
A Phase 2 study of NAFLD and NASH, sponsored by Neuraly.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 12
- Study locations
NCT06410924: Active Phase 2 study of NAFLD and NASH, sponsored by Neuraly.
NCT06410924 is a Phase 2 study of NAFLD and NASH that is active but no longer recruiting, run by Neuraly. The registered enrollment target is 67 participants, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (59% lower). The trial reports 12 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06410924, a Phase 2 study of NAFLD and NASH, is active but no longer recruiting, sponsored by Neuraly.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Interventions
- DRUG Placebo
- DRUG DD01
Study Locations (12)
Texas
- Summit Research Site - Austin
- Summit Research Site - Bellaire
- Summit Research Site - Brownsville
- Summit Research Site - Corpus Christi
- Summit Research Site - Edinburg
- Summit Research Site - Georgetown
- Summit Research Site - San Antonio
- Summit Research Site - San Antonio
Louisiana
- Summit Research Site - Monroe
- Summit Research Site - West Monroe
Florida
- Summit Research Site - Maitland
Missouri
- Summit Research Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT06410924 still lists
NCT06410924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with NAFLD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06410924 lists 12 locations in 4 states (Texas, Louisiana, Florida).
Frequently Asked Questions
What is clinical trial NCT06410924 about?
NCT06410924 is a clinical study titled "A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH". This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
What is the current status of trial NCT06410924?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2024-06-13. Estimated completion is 2026-06.
What conditions does trial NCT06410924 study?
This clinical trial studies the following conditions: NAFLD, NASH.
What interventions are being tested in trial NCT06410924?
The interventions under investigation include: Placebo (DRUG), DD01 (DRUG).
Who is sponsoring clinical trial NCT06410924?
This trial is sponsored by Neuraly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06410924 being conducted?
This trial has 12 study locations across Florida, Louisiana, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06410924's enrollment target sits among peer trials
67 15th of 26 higher than 12 of 26 other NAFLD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NAFLD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RECRUITING · Phase 2
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
COMPLETED · Phase 2
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI